Impact Biomedical (IBO) Net Income (2022 - 2026)
Impact Biomedical's (IBO) quarterly Net Income came in at -$2.3 million in Q1 2026, down 78.72% YoY from -$10.7 million in Q1 2025, and down 54.85% on a QoQ basis from -$1.5 million in Q3 2025.
Impact Biomedical (IBO) Net Income (2022 - 2026) Analysis & Trends
Impact Biomedical (IBO) has 5 years of Net Income data on file, last reported at -$2.3 million in Q1 2026.
- Quarterly Net Income fell 78.72% year-over-year to -$2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$18.1 million (up 27.62% YoY) and the FY2024 annual result came in at -$24.8 million, down 462.06% from the prior year.
- Net Income declined to -$2.3 million in Q1 2026, from -$1.5 million in the prior quarter.
- In the past five years, Net Income ranged from a high of $4.2 million in Q3 2024 to a low of -$27.1 million in Q4 2024.
- A 5-year average of -$3.7 million and a median of -$1.3 million in 2023 frame the typical range for Net Income.
- The widest YoY moves for Net Income: up 460.32% in 2024, down 2049.09% in 2024.
- Tracing IBO's Net Income over 5 years: stood at -$3.4 million in 2022, then jumped by 62.54% to -$1.3 million in 2023, then sank by 2049.09% to -$27.1 million in 2024, then soared by 94.56% to -$1.5 million in 2025, then sank by 54.85% to -$2.3 million in 2026.
- The last three Net Income figures came in at -$2.3 million (Q1 2026), -$1.5 million (Q3 2025), and -$14.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -355.03 Mn |
| 10 | Impact Biomedical | 49.45 Mn | 49.44 Mn | 2,000.00 | -700,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -700,000.00 |
| Mar 31, 2026 | -2.28 Mn |
| Sep 30, 2025 | -1.48 Mn |
| Jun 30, 2025 | -14.35 Mn |
| Mar 31, 2025 | -1.28 Mn |
| Dec 31, 2024 | -27.10 Mn |
| Sep 30, 2024 | 4.24 Mn |
| Jun 30, 2024 | -884,000.00 |
| Mar 31, 2024 | -998,000.00 |
| Dec 31, 2023 | -1.26 Mn |
| Sep 30, 2023 | -1.18 Mn |
| Jun 30, 2023 | -1.12 Mn |
| Mar 31, 2023 | -849,000.00 |
| Dec 31, 2022 | -3.37 Mn |
| Sep 30, 2022 | -2.24 Mn |
| Jun 30, 2022 | -799,000.00 |